- Moneycontrol /
- Market /
- Pharmaceuticals /
- BALANCE SHEET
BSE Live
Feb 20, 16:00Prev. Close
317.90
Open Price
319.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 20, 15:57Prev. Close
318.10
Open Price
318.10
Bid Price (Qty.)
321.55 (664)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Glenmark Pharma (in Rs. Cr.) | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 | |
| Total Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 | |
| Reserves and Surplus | 11,913.87 | 10,363.22 | 9,408.40 | 7,337.75 | 4,924.92 | |
| Total Reserves and Surplus | 11,913.87 | 10,363.22 | 9,408.40 | 7,337.75 | 4,924.92 | |
| Total Shareholders Funds | 11,942.09 | 10,391.44 | 9,436.62 | 7,365.96 | 4,952.05 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 2,831.45 | 2,686.03 | 2,589.35 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 132.40 | |
| Other Long Term Liabilities | 88.51 | 2.60 | 2.41 | 4.70 | 121.92 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 2,919.96 | 2,688.63 | 2,591.75 | 4.70 | 254.32 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 303.03 | 295.04 | 187.19 | 787.42 | 347.60 | |
| Trade Payables | 1,667.66 | 1,554.95 | 1,467.09 | 1,625.95 | 1,566.79 | |
| Other Current Liabilities | 224.63 | 256.45 | 276.52 | 299.78 | 378.70 | |
| Short Term Provisions | 85.33 | 78.36 | 41.37 | 29.21 | 151.38 | |
| Total Current Liabilities | 2,280.65 | 2,184.80 | 1,972.18 | 2,742.35 | 2,444.47 | |
| Total Capital And Liabilities | 17,142.70 | 15,264.87 | 14,000.55 | 10,113.01 | 7,650.84 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 1,308.17 | 1,576.65 | 1,470.50 | 1,321.92 | 1,152.48 | |
| Intangible Assets | 105.32 | 122.47 | 125.87 | 116.08 | 78.19 | |
| Capital Work-In-Progress | 209.18 | 354.04 | 235.14 | 260.93 | 286.48 | |
| Fixed Assets | 1,699.68 | 2,118.80 | 1,867.03 | 1,714.07 | 1,524.87 | |
| Non-Current Investments | 3,268.75 | 3,212.68 | 1,866.70 | 1,858.43 | 1,659.52 | |
| Deferred Tax Assets [Net] | 712.13 | 660.62 | 594.06 | 401.16 | 0.00 | |
| Long Term Loans And Advances | 6,263.93 | 3,302.85 | 3,642.68 | 1,447.32 | 854.63 | |
| Other Non-Current Assets | 57.06 | 94.68 | 79.24 | 64.11 | 13.86 | |
| Total Non-Current Assets | 12,001.54 | 9,389.62 | 8,049.72 | 5,485.08 | 4,052.88 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 911.21 | 1,111.18 | 1,145.06 | 968.00 | 736.63 | |
| Trade Receivables | 2,087.13 | 3,828.91 | 3,879.40 | 3,057.66 | 2,440.83 | |
| Cash And Cash Equivalents | 256.48 | 177.38 | 252.18 | 74.24 | 48.55 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 356.32 | |
| OtherCurrentAssets | 1,886.33 | 757.78 | 674.19 | 528.03 | 15.62 | |
| Total Current Assets | 5,141.15 | 5,875.25 | 5,950.83 | 4,627.93 | 3,597.96 | |
| Total Assets | 17,142.70 | 15,264.87 | 14,000.55 | 10,113.01 | 7,650.84 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 3,894.11 | 5,216.10 | 4,317.09 | 4,939.63 | 5,878.77 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 495.35 | 396.93 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 71.88 | 71.10 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 2,285.86 | 3,720.76 | 808.41 | 553.94 | 617.59 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | 0.01 | 0.02 | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | 3,720.76 | 5,615.16 | 3,304.35 | 2,972.05 | |
| Other Earnings | 6,299.84 | -- | -- | 390.12 | 157.87 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 15.84 | 15.84 | 15.84 | 15.84 | 15.84 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.10 | 0.10 | 0.14 | 0.10 | 0.19 | |
| Non-Current Investments Unquoted Book Value | 3,268.65 | 3,212.68 | 1,866.56 | 1,858.33 | 1,659.47 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
22.01.2020
Glenmark Pharma sells gynaecology business, share price gains
07.01.2020
Granules India, Glenmark Pharma rally 3% on drug approvals from USFDA
16.12.2019
Glenmark Pharma receives GMP certificate from European regulator; share price gains 3%
18.11.2019
Glenmark Pharma share price ends 22% higher after CLSA upgrades stock to buy
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015
